How AI Is Aiming at the Bad Math of Drug Development

The Virtuous Cycle: Innovation and Investment

Exscientia Files For $100M IPO

UK life science attracts £850m deal

Innovation at the intersection of design and technology

Exscientia : Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering With Full Exercise of Underwriters' Option to Purchase Additional ADSs and $160.0 Million Concurrent Private Placement

Chamath Palihapitiya – Venture Capital – Silicon Valley Ponzi Scheme

Biopharma Collaboration Is Key For Innovation

Discovering the next unicorn founder with data, not gut instinct

UBS clients raise $650 mln for biggest yet biotech impact fund